Conjunctive cognitive behavioral therapy and SSRI treatment may reduce the symptoms and impaired social functioning associated with obsessive-compulsive disorder more effectively than medication alone.
Reduced fetal growth was associated with a small but significant increase in the general risk for psychiatric and neurodevelopmental disorders.
Study data found that a single 60-minute interview session may be sufficient for capturing obsessive-compulsive symptoms in youth.
A study compared participants with clear diagnoses of either generalized anxiety disorder or obsessive-compulsive disorder with each other, as well as with controls, in order to identify cognitive differences between both groups.
Intensive residential treatment was found to be effective in reducing the symptoms of obsessive-compulsive disorder, although different response trajectories were observed.
Transcranial magnetic stimulation (TMS) uses magnetic fields to stimulate nerve cells in the brain.
Researchers examined whether adjunctive gabapentin or memantine and standard treatment with a selective serotonin-reuptake inhibitor (SSRI) might lead to further improvements in patients with OCD.
A brain stimulation device to treat OCD has received approval for marketing by the US Food and Drug Administration.
These results identify several predictive factors for remission in children with OCD and may be useful for clinicians in tailoring their treatment approach, although the impact of adjunctive d-cycloserine requires further investigation.
Unexpected presentations of OCD can put children at risk of receiving diagnoses or treatments that do not address their underlying obsessions.
